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Background: Prior to carrying out clinical trials, it is important to assess the health status of the study participants
to be able to interpret subsequent changes thatmaybe related to the effects of the treatments during the follow-
up of patients. This study presents the clinical, haematological and biochemical profiles of podoconiosis patients
prior to their involvement in the PodoLEDoxy clinical trial.
Methods: All lower limb lymphoedema patients visiting the centre were screened and a podoconiosis diagnosis
was based on clinical manifestation and detailed medical history. Patients who satisfied the eligibility criteria
were enrolled in the study and their demographic data, vital signs and medical history were collected followed
by biochemical and haematological examinations.
Results: Of the 222 participants enrolled in the study, 55.4% and 41.4% had either stage 3 or 2 podoconiosis
as their highest stages, respectively. On physical examination, gastritis (46%) and poor vision (2.7%) were the
most prevalent health issues identified. The majority of haematological and biochemical values were within the
normal range except for mean platelet volume (47.7%), plateletcrit (58.1%), platelet distribution width (66.2%),
mean corpuscular volume (67.6%) and red cell distribution width-standard deviation (79.3%), where >40% of
the study participants had values out of the normal.
Conclusion: The clinical, haematological and biochemical profiles of the study participants were largely within
the normal range except for certain haematological parameters that might be worth investigating.
Keywords: biochemical, clinical, haematological, lymphodema, podoconiosis, profiling
Introduction
Lower limb lymphoedema is caused by several neglected trop-
ical diseases such as podoconiosis, lymphatic filariasis (LF) and
leprosy. While the latter two conditions are caused by a parasite
and bacterium, respectively, podoconiosis is a non infectious dis-
ease associated with the exposure of bare feet to irritant alkaline
red clay soils.1–4
Podoconiosis is locally known as ‘mossy foot’ and causes
massive swelling of the lower legs and feet resulting in heavy
aching discomfort, which limits a person’s ability to use his or
her legs.5 It increases the risk to certain infections, causes emo-
tional distress, depression and stigmatisation in the affected
person. This imposes huge burdens on affected individuals,
their families and communities, resulting in a loss of economic
productivity.6–10
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access
article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
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Podoconiosis arises mostly in barefoot subsistence farmers
after long-term exposure to irritant red clay soils.11,12 Swelling
occurs on the lower limbs and ascends, starting in the foot and
progressing to the knee. It has been classified into five stages
based upon severity, with stage 5 being the most severe stage.13
Podoconiosis was identified as a neglected tropical disease by
the WHO in 2011.14 Approximately 20 million people worldwide
are thought to be affected by lymphoedema, 4 million cases of
which are due to podoconiosis.15,16 It is a major health prob-
lem in developing countries and has been reported in more than
32 countries in Africa, Latin America and South East Asia.11,15 It
affects people of all ages, but is more prevalent among older age
groups. However, females are more affected due to the nature
of their activities, such as farming.4 The recent nationwide map-
ping of podoconiosis in Cameroon reported a 0.5% prevalence
of lower limb lymphoedema, of which 62.7% were podoconiosis
cases. This also highlighted the Northwest Region of Cameroon as
an endemic area recording the highest prevalence (1.7%) among
all 10 regions.17,18
To date, there is no specific diagnostic tool for defining podoco-
niosis; the diagnosis is made solely on the basis of medical his-
tory and clinical examination, coupled with the exclusion of other
causes of lower limb lymphoedema.19 Although there has been
a significant improvement over the last few years in the man-
agement of podoconiosis cases,20 much has still to be learned
to improve on its diagnosis and treatment. Knowledge of the
clinical and laboratory patterns of people with lower limb lym-
phoedema due to podoconiosis is of interest because it presents
opportunities for the diagnosis of podoconiosis, but interestingly,
to date no studies have been conducted to investigate the clinical
and laboratory features of podoconiosis patients. There is, there-
fore, a need to understand the clinical, haematological and bio-
chemical profiles of patients with lymphoedema of non-filarial
origin (podoconiosis) with the aim of identifying patterns unique
to the disease. In addition, some of the measurements can also
be indicative of the burden of other non-communicable diseases
among podoconiosis patients that have clinical and program-
matic implications.21,22 These patterns can open up avenues that
might serve as biomarkers to discriminate podoconiosis from
other diseases that cause lymphoedema.
The aim of this study was to describe the clinical, haema-
tological and biochemical profiles of podoconiosis patients in
the Northwest Region of Cameroon screened prior to their
involvement in the Doxycycline for treatment of non-filarial lym-
phoedema due to podoconiosis (TAKeOFF PodoLEDoxy) clinical
trial. This was a randomised, double-blind, placebo-controlled,
phase II trial to determine if a doxycycline treatment regimen of




This study was conducted at a lymphoedema clinical trial centre
(PodoLedoxy clinical trial centre) situated at Foncha Street Nkwen
(with the coordinates 5.9811374 and 10.1706479) in Bamenda,
the headquarters of the Northwest Region of Cameroon. It is
located 366 km northwest of the capital, Yaoundé. Participants
in the study resided in 11 of 19 health districts in the North West
Region of Cameroon that had the highest prevalence (1.7%) of
podoconiosis.17 The health districts were Bafut, Bali, Bamenda,
Batibo, Fundong, Kumbo, Ndop, Ndu, Nkambe, Santa and Tubah,
which have an estimated total population of approximately 1 548
926 people.
Study design and period
A cross-sectional study was conducted from April to December
2019. Figure 1 presents the flowchart of recruitment and the
number of individuals whowere excluded and eligible for the clin-
ical trial.
Study population
The study population consisted of all lymphoedema patients clin-
ically suspected of podoconiosis when visiting the lymphoedema
clinical trial centre within the study period.
Inclusion and exclusion criteria
The following inclusion criteria were used: people with stage 2
and/or 3 podoconiosis in at least one leg, age 18–60 y, body
weight ≥40 kg, residing in a podoconiosis-endemic district for
≥2 y and testing negative for LF using Filarial Test Strip. The
following exclusion criteria were used: individuals who do not
fulfil the inclusion criteria, pregnant women and breastfeed-
ing mothers, lymphoedema due to other causes, HIV, podoco-
niosis patients with alanine aminotransferase (ALT) >80 U/L,
aspartate aminotransferase (AST) >80 U/L, gamma-glutamyl
transferase (γ -GT)>100 U/L, serum creatinine >2.8 mg/dL, neu-
trophil <1100/mm3, haemoglobin <8 g/dL and platelets <100
000/mm3.
Study variables
The following key variables were measured in the study:
 Sociodemographic variables: gender, age, occupation and
duration in the community (endemicity);
 Clinical variables: blood pressure, pulse rate, temperature,
weight, physical examination and medical history;
 Haematological variables: white (WBC) and red blood cell (RBC)
count, haemoglobin (HGB), haematocrit (HCT), mean corpus-
cular volume (MCV), mean corpuscular haemoglobin concen-
tration (MCHC), mean corpuscular haemoglobin (MCH), red cell
distribution width (RDW), platelet count (PLT), mean platelet
volume (MPV), plateletcrit (PCT) and platelet distribution width
(PDW).
 Biochemical variables: ALT, AST, γ -GT and serum creatinine.
Urinalysis: specific gravity, protein, blood, glucose, nitrite, pH,
ketone, bilirubin, urobilinogen and leucocytes.
Case identification
A total of 222 podoconiosis patients were screened for enrol-
ment to the clinical trial after obtaining their informed consent.
All lower limb lymphoedema patients who visited the centre
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Figure 1. Flowchart of activities.
experience in podoconiosis diagnosis. Diagnosis was based on
clinical manifestation and detailed medical history, followed by
staging using the five-point scale of Tekola et al.13 Confirmed
podoconiosis participants who satisfied all the eligibility criteria
were retained and enrolled in the study. Patient’s demographic
data were recorded; their vital signs were measured and medical
history recorded.
Sample collection, processing and transportation
Samples (blood and urine) were collected in the laboratory unit of
the centre and labelledwith the date of collection and participant
code. In the centre, 50–60 mL of midstream urine was collected
in sterile urine cups for urinalysis with a urinalysis dip stick (URIT
11G; Urit Medical Electronic Co., Ltd, Guangxi); pH, glucose, pro-
tein, blood, nitrite, ketone, bilirubin, urobilinogen, specific gravity
and leucocyteswere the parameters assessed using the collected
urine samples.
A total of 6 mL of venous blood was collected through
venepuncture from each study participant. Next, 4 mL of blood
was collected into an EDTA tube for biochemical analysis and
2 mL into a clot activator tube (BD Vacutainer, UK) for haema-
tological analysis. The laboratory request form was completed
and the sample collection time noted. Whole blood and serum
sampleswere transported to the Bamenda Regional Hospital Lab-
oratory for analysis. The 2 mL blood samples collected in the
clot activator tubes were centrifuged at a speed of 2000x g for
10 min and 500 µL of serum was extracted and aliquoted into
labelled Eppendorf tubes. To exclude LF as a possible cause of
lymphoedema in lymphoedema individuals, 75 µL of capillary
blood was collected to perform the Alere filarial test (Alere Scar-
borough, Inc., USA) according to the manufacturer’s instructions.
Laboratory examination
The EDTA tube containing 4 mL whole blood and the Eppendorf
tube containing 500 µL were packaged into iceboxes (4°C) and
transported within 4–5 h to the Bamenda Regional Hospital Lab-
oratory, which is situated approximately 6.2 km from the centre.
The samples were received and documented by the laboratory
reception staff along with the test request forms upon arrival.
The samples were forwarded to the various laboratory units
(biochemistry and haematology) and analyses were performed
immediately. ALT, AST, γ -GT and serum creatinine were mea-
sured using an automated biochemical analyser (BIOSMART 240;
Bionline S.R.L, Chile) according to the manufacturer’s instruc-
tions. Result outputswere projected onto the screen, verified then
printed out.
The haematological parameters were determined using an
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Table 1. Sociodemographic characteristics of study population
Podoconiosis subjects (n=222)
Class Frequency %




Gender Female 192 85.7
Male 32 14.3






Farmer + (other) 14 6.25
Podoconiosis stage Stage 2 92 41.07
Stage 3 123 54.91
Stage 4 07 3.42
Electronic Group Co., Ltd, China), which performs full blood
counts. To determine the differentialWBC count, two experienced
personnel independently counted the blood cells and the average
for each cell typewas calculated and recorded. After analysis, the
results for each participantwere validated by the laboratory head,
placed in sealed envelopes then made available for collection at
reception.
Quality control
Biochemical and haematological analysis were performed in
accordance with the standard operating protocol and the
manufacturer’s instructions. The test was conducted in a
certified laboratory by trained and certified laboratory tech-
nologists with experience in the use of automated analy-
sers. For every automated machine, daily quality assurance
checks were performed in accordance with the manufacturer’s
recommendations.
Ethical considerations
Ethical approval was obtained from the National Ethics Com-
mittee for Health Research on Humans (CNERSH) and the clini-
cal trial is registered under International Standard Randomised
Controlled Trial Number (ISRCTN) 11881662. Individual informed
consent was obtained from each participant. Patient information
sheets, assent and consent forms were printed in French and
English, the official languages of Cameroon. Confidentiality was
assured by assigning unique codes to all participants and their
identification files were kept in a secured locker.
Data analysis
Data were entered by two data clerks using REDCap software
secure web application (REDCap 7.0.6 -Vanderbilt University,
Nashville, TennesseeUSA. https://www.project-redcap.org), com-
pared, then any inconsistencies corrected. The validated data
were then exported to Excel 2013 (Microsoft Corporation, Red-
mond, Washington, USA) and analysed using SPSS version 20
(IBM SPSS Statistics, Armonk, NY, US). Summary frequency tables
were generated and parameters were categorised into normal
and abnormal based on reference ranges set by the trial and the
reference laboratory of the Bamenda Regional Hospital.
Results
Sociodemographic data
In total, 222 individuals with podoconiosis were included in the
study, of whom 191 (86%) and 31 (14%) were females and
males, respectively. One hundred and thirty of the participants
were aged >40 y and the occupation of 113 (50.9%) was farm-
ing. The majority of participants had either stage 3 (55.4%) or
stage 2 (41.4%) podoconiosis as their highest stages (Table 1).
Vital signs and comorbidities
Clinically, most of the participants had vital signs within the nor-
mal range, with five of them being hypertensive (Table 2). Upon
physical examination, the most prevalent health issues identified
were gastritis (21/222; 9.46%) and poor vision (6/222; 2.7%). Evi-
dence of surgery was also observed in 12 participants (5.41%)
(Supplementary Table 1). The following reported comorbidities
Table 2. Vital sign presentation of study participants
Reference ranges Class Frequency %
Temperature 36.5–37.5 Normal 220 99.1
High 2 0.9
Pulse 60–100 Normal 220 99.1
Low 2 0.9
Blood pressure <120/80 Normal 169 76.1
>130/80–120 High blood pressure 48 21.6
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Table 3. Haematological profiles of study participants
Stage 2 Stage 3 Stage 4
Parameter Classification n (%) n (%) n (%) Total n (%) Reference range
WBC (x 102 µl) Normal 69 (75.0) 95 (77.20) 5 (71.40) 169 (76.10) 4.0–10.0
Abnormal 23 (25.0) 27 (22.0) 2 (28.60) 52 (23.40)
HCT(%) Normal 71 (77.20) 75 (61.00) 5 (71.40) 151 (68.00) 36.0–48.0
Abnormal 21 (22.80) 47 (38.20) 2 (28.60) 70 (31.50)
HBG (g/dL) Normal 92 (100.00) 122 (99.20) 7 (100.00) 221 (99.50) 11.0–15.0
MCV Normal 32 (34.80) 37 (30.10) 2 (28.60) 71 (32.00) 80.0–99.0
Abnormal 60 (65.20) 85 (69.10) 5 (71.40) 150 (67.60)
Eosinophil (%) Normal 63 (68.50) 79 (64.20) 3 (42.90) 145 (65.30) 1–6
Abnormal 29 (31.50) 44 (35.80) 4 (57.10) 77 (34.70)
Monocytes (%) Normal 75 (81.50) 94 (76.40) 7 (100.00) 176 (79.30) 2–10
Abnormal 17 (18.50) 28 (22.80) 0 (0.00) 45 (20.30)
Lymphocytes (%) Normal 53 (57.60) 77 (62.60) 4 (57.10) 134 (60.40) 21–45
Abnormal 39 (42.40) 45 (36.60) 3 (42.90) 87 (39.20)
Neutrophil (%) Normal 90 (97.80) 119 (96.70) 7 (100.00) 216 (97.30) 45–75
Abnormal 2 (2.20) 3 (2.40) 0 (0.00) 5 (2.30)
PCT (%) Normal 33 (35.90) 55 (44.70) 4 (57.10) 92 (41.40) 0.10–0.28
Abnormal 59 (64.10) 67 (54.50) 3 (42.90) 129 (58.10)
PDW Normal 30 (32.60) 42 (34.10) 2 (28.60) 74 (33.30) 10.0–14.0
Abnormal 62 (67.40) 80 (65.00) 5 (71.40) 147 (66.20)
MPV (fL) Normal 43 (46.70) 66 (53.70) 6 (85.70) 115 (51.80) 7.4–10.4
Abnormal 49 (53.30) 56 (45.50) 1 (14.30) 106 (47.70)
MCHC (g/dL) Normal 76 (82.60) 101 (82.10) 5 (71.40) 182 (82.00) 32.0–36.0
Abnormal 16 (17.40) 21 (17.10) 2 (28.60) 39 (17.60)
PLT (10ˆ3uL) Normal 92 (100.00) 122 (99.20) 6 (85.70) 220 (99.10) 100–300
Abnormal 0 (0.00) 0 (0.00) 1 (14.30) 1 (0.50)
RDWSD (fL) Normal 20 (21.70) 24 (19.50) 1 (14.30) 45 (20.30) 39.0–46.0
Abnormal 72 (78.30) 98 (79.70) 6 (85.70) 176 (79.30)
RDWCV (%) Normal 66 (71.70) 78 (63.40) 5 (71.40) 149 (67.10) 11.5–14.5
Abnormal 26 (28.30) 44 (35.80) 2 (28.60) 72 (32.40)
MCH (pg) Normal 67 (72.80) 88 (71.50) 2 (28.60) 157 (70.70) 26.0–32.0
Abnormal 25 (27.20) 34 (27.60) 5 (71.40) 64 (28.80)
HCT, haematocrit; HGB, haemoglobin; MCH, mean corpuscular haemoglobin; MCHC, corpuscular haemoglobin concentration; MCV, mean cor-
puscular volume; MPV, mean platelet volume; PCT, plateletcrit; PDW, platelet distribution width; PLT, platelet count; RDWSD, red cell distribution
width-standard deviation; RDWCV, red blood cell distribution coefficient of variation; WBC, white blood cell.
were identified: gastritis (10), hypertension (9), diabetes mellitus
(2), leg ulcer (2), asthma (1), cataract (1) and tinea versicolor (1)
(Supplementary Table 2).
Haematological profiles
The haematological parameters were within the normal range
(Table 3). However, for MPV (47.7%), PCT (58.1%), PDW (66.2%),
MCV (67.6%) andRDWSD (79.3%),>40%of the study participants
had values outwith the normal range (Supplementary Table 3).
Similar observations were made regarding RBC, WBC and the
platelet picture, as no abnormalities were prevalent within a par-
ticular group of study participants. The abnormalities recorded for
RBC,WBC and platelets are presented in Table 4. For the blood pic-
ture, 17.6% of study participants had microcytic red blood cells;
10.4%of the participants had neutropenia and 22.5%had throm-
bocytosis.
Biochemical profiles
The biochemical profiles of blood serum were within the normal
range for most participants. Less than 3% of the study partic-
ipants had abnormal ALT, AST and γ -GT values while 9% had
abnormal creatinine (Table 5). Biochemical measurements of
urine for a majority of participants were also within the normal
range (Supplementary Table 4).
Discussion
The PodoLEDoxy clinical trial aims to test the efficacy of a
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Table 4. Red blood cell, white blood cell and platelet picture of
study subjects
Cell type Frequency %








RBC shape Burr cell 8 3.6
Rouleux formation 9 4.1
Ovalocyte 16 7.2
WBC Normal 123 55.4
Scanty 48 21.6








Platelet Normal 164 73.9
Thrombocytosis 50 22.5
Giants 48 21.6
Large forms 14 6.3
HB, hemoglobin; RBC, red blood cells; WBC, white blood cell.
lymphoedema caused by podoconiosis. This is a phase II trial
involving the administration of 200 mg/d of doxycycline treat-
ment for 6 wk that has been shown to halt or improve disease
severity in filarial lymphoedema.23 Building on the successes of
the regimen in filarial lymphoedema, the trial seeks to deter-
mine if a similar outcome can be observed with non-filarial lym-
phoedema. Prior to carrying out clinical trials, it is important
to assess the health status of participants. This study therefore
presents the clinical, haematological and biochemical profiles of
podoconiosis study participants screened for enrolment in the
trial.
To the best of our knowledge, this is the first study attempt-
ing to investigate and document the clinical, haematological and
biochemical profiles of podoconiosis patients. Because of the long
duration of the treatment regimen, which exerts significant pres-
sure on liver function, profiling these individuals with a health
condition that has no specific diagnostic and treatment tool is
important.
On clinical examination, most of the participants were clini-
cally fit except for stage 2 and 3 lymphoedema, which was of
interest in the PodoLEDoxy clinical trial. This is clearly demon-
strated by the fact that 75.7% and 69.0% had no comorbidities
or health issues upon physical examination, respectively. This is
important because it ensures that the values measured in our
study largely reflected effects due to the podoconiosis condition
and were not attributable to any other comorbidity that could
have significantly affected the parameters investigated. In addi-
tion, it also ensures that during trial follow-ups, it is easier to iden-
tify any effect of the doxycycline treatment.
With respect to the haematological profiles, a significant pro-
portion of the participants had values outwith the normal range.
The most noticeable abnormality was the size and proportion of
platelets (PDW and PCT) and red blood cells (RDW and MCV). The
blood picture also revealed a considerable percentage of micro-
cytic RBC in participants. This abnormality is associated with sev-
eral diseases or a clinical state such as thalassemia, anaemia of
chronic inflammation, lead poisoning, iron deficiency anaemia
or sideroblastic anaemia.24,25 Since the major morbidity in our
study participants is podoconiosis, abnormalities in the param-
eters mentioned may be a consequence of lymphoedema and
thus may merit further investigation. Examining the biochemical
profiles, the liver and kidney function parameters measured were
largely within the normal range, indicating that the liver and kid-
ney might not be implicated in podoconiosis disease.
This study was limited to profiling the clinical, haematological
and biochemical profiles of podoconiosis patients who satisfied
Table 5. Biochemical parameters of blood serum in between control and all podoconiosis participants
Stage 2 Stage 3 Stage 4
Parameter Classification n (%) n (%) n (%) Total n (%) Reference range
Creatinine (mg/dl) Normal 88 (95.70%) 106 (86.20) 7 (100.00) 201 (90.50) 0.7–2.8
Abnormal 4 (4.30) 16 (13.00) 0 (0.00) 20 (9.00)
γ -GT (U/L) Normal 90 (97.80) 118 (95.90) 7 (100.00) 215 (96.80) 11–100
Abnormal 2 (2.20) 4 (3.30) 0 (0.00) 6 (2.70)
AST (U/L) Normal 91 (98.90) 119 (96.70) 7 (100.00) 217 (97.70) 0–80
Abnormal 1 (1.10) 3 (2.40) 0 (0.00) 4 (1.80)
ALT (U/L) Normal 90 (97.80) 121 (98.40) 7 (100.00) 218 (98.20) 0–80
Abnormal 2 (2.20) 1 (0.80) 0 (0.00) 3 (1.40)
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the baseline eligibility criteria for participating in the PodoLEDoxy
clinical trial. Thus, it did not include podoconiosis patients with
underlying comorbid conditions, which could have significantly
affected the parameters measured. By contrast, this strength-
ened the study because its results could be related more directly
to podoconiosis as, in large part, the participants did not have
any other comorbid conditions that could significantly affect the
results.
With large gaps still remaining in the understanding of the
immunology and pathophysiology of podoconiosis, studying
the clinical and laboratory profiles of podoconiosis participants
screened for the clinical trial was an opportunity to explore poten-
tial patterns associatedwith peoplewith podoconiosis. Therefore,
the information presented might identify and open avenues for
further clinical studies or research.
Conclusion
Upon physical examination, 68.92% of the enrolled participants
presentedwith nomedical condition, while gastritis (9.46%), poor
vision (4.05%) and hypertension (2.25%) were themost recorded
comorbid conditions. The haematological profileswerewithin the
normal range for most study participants. High proportions of
participantswith abnormal haematological valueswere recorded
for MPV (47.7%), PCT (58.1%), PDW (66.2%), MCV (67.6%) and
RDWSD (79.3%). For the biochemical parameters, >97% of the
study participants had measurements within the normal range.
Supplementary data
Supplementary data are available at Transactions online.
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